 Our theme of Gene Editing stocks remains down by about 11 year-to-date, considerably underperforming the SP 500 which is up by a solid 23 over the same period. The theme would have actually declined by about 46 year-to-date if we exclude a single stock, Intellia Therapeutics, which is up by. 